GlassScriptPhysician profile
Krupa Patel
NPI 1013240357
$281,196.07
in general payments reported to CMS, 2019-2025
33 companies · $52K in 2025
The $52K reported for 2025 was more than what 99% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,031 · 2020: $24K · 2021: $23K · 2022: $36K · 2023: $57K · 2024: $86K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $165K · Travel and Lodging: $22K · Food and Beverage: $7,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $165,218.75 |
| Travel and Lodging | $21,605.12 |
| Food and Beverage | $7,662.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $277,288.58 | 2019-2025 | Ortholoc 2 Lapifuse, Prostep, Hoffmann |
| Novus Surgical Solutions LLC | $1,212.45 | 2021-2022 | |
| Averitas Pharma INC. | $645.37 | 2023-2024 | Qutenza |
| Organogenesis INC. | $256.67 | 2021 | |
| Kerecis Limited | $224.65 | 2021-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Grt US Holding, INC. | $158.99 | 2022 | |
| Integra Lifesciences Corporation | $154.03 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Kowa Pharmaceuticals America, INC. | $147.03 | 2022-2023 | Seglentis |
| Smith+Nephew, INC. | $117.06 | 2020-2024 | Collagenase Santyl, Regranex |
| Musculoskeletal Transplant Foundation INC. | $109.68 | 2021-2024 | |
| Lifenet Health | $97.48 | 2025 | Theragenesis Wound Matrix |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.63 | 2020-2024 | Jublia |
| Nevro Corp. | $82.14 | 2022-2024 | Senza |
| Tactile Systems Technology INC | $73.48 | 2023-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Convatec INC. | $61.56 | 2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $41.82 | 2022-2024 | Tapestry |
| Osiris Therapeutics INC. | $39.22 | 2019 | |
| Depuy Synthes Sales INC. | $38.86 | 2023 | Hammerlock |
| Hydrocision, INC. | $37.02 | 2023 | Tenjet |
| Abbvie INC. | $36.14 | 2021-2025 | |
| Abbott Laboratories | $32.96 | 2021-2024 | Proclaim |
| Arthrosurface Incorporated | $32.52 | 2019 | |
| Treace Medical Concepts, INC. | $32.28 | 2024-2025 | |
| Reapplix INC. | $31.76 | 2024 | 3c Patch Kit - Box |
| Misonix INC | $21.99 | 2019 | |
| Merck Sharp & Dohme LLC | $20.95 | 2025 | Capvaxive, Gardasil 9 |
| Next Science LLC | $20.62 | 2020 | |
| Amgen INC. | $19.34 | 2025 | Krystexxa |
| Solventum Corporation | $16.91 | 2025 | V.A.C.Ulta |
| Paratek Pharmaceuticals, INC. | $14.67 | 2022 | |
| Paragon 28, INC. | $13.50 | 2024 | Silverback |
| Ibsa Pharma INC. | $13.47 | 2023 | Tirosint, Licart |
| Alfasigma USA, INC. | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krupa Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.